bismuth has been researched along with Neuroendocrine Tumors in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruchertseifer, F; Flechsig, P; Giesel, FL; Haberkorn, U; Kratochwil, C; Kuder, T; Schwartz, LH; Wulfert, S; Zechmann, CM | 1 |
| Apostolidis, C; Boll, R; Bruchertseifer, F; Giesel, FL; Haberkorn, U; Kratochwil, C; Mier, W; Morgenstern, A; Murphy, K | 1 |
1 trial(s) available for bismuth and Neuroendocrine Tumors
| Article | Year |
|---|---|
Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy.
Topics: Bismuth; Contrast Media; Infusions, Intra-Arterial; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Perfusion Imaging; Positron-Emission Tomography; Radioisotopes; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2013 |
2 other study(ies) available for bismuth and Neuroendocrine Tumors
| Article | Year |
|---|---|
²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.
Topics: Adult; Alpha Particles; Beta Particles; Bismuth; Female; Humans; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radioisotopes; Receptors, Somatostatin; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure | 2014 |
SNM 2012 image of the year.
Topics: Bismuth; Humans; Intestinal Neoplasms; Liver; Neuroendocrine Tumors; Nuclear Medicine; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Societies, Scientific; Stomach Neoplasms; Treatment Failure | 2012 |